Auro Laboratories Ltd
NSE: BSE: 530233
₹279.95
(-1.77%)
Wed, 11 Mar 2026, 09:08 pm
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KAuro Laboratories Analysis
dividend
- Unable to evaluate Auro Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Auro Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Auro Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Auro Laboratories is profitable, therefore cash runway is not a concern.
- Auro Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (290.7%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 4.4x debt.
- Auro Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (227.1% vs 19.1% today).
- Interest payments on debt are well covered by earnings (EBIT is 16.1x coverage).
- Auro Laboratories's level of debt (19.1%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- Sharat's compensation has been consistent with company performance over the past year, both up more than 20%.
- Sharat's remuneration is higher than average for companies of similar size in India.
misc
- Auro Laboratories is not covered by any analysts.
- Auro Laboratories has significant price volatility in the past 3 months.
past
- Auro Laboratories has delivered over 20% year on year earnings growth in the past 5 years.
- Auro Laboratories used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Auro Laboratories has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Auro Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Auro Laboratories's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (40.6% vs 22.7%).
- Auro Laboratories's 1-year earnings growth is less than its 5-year average (40.6% vs 42.6%)
value
- Auro Laboratories's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Auro Laboratories's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Auro Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- Auro Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Auro Laboratories is good value based on earnings compared to the India market.
- 530233 outperformed the Market in India which returned -14.5% over the past year.
- BSE:530233 is up 29.1% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530233 is up 29.1% outperforming the market in India which returned 8% over the past month.
- 530233 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800